VIEMED HEALTHCARE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.145 USD | +0.21% |
|
-12.76% | -8.98% |
| May. 07 | Transcript : Viemed Healthcare, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
| May. 06 | Earnings Flash (VMD) VIEMED HEALTHCARE Reports Q1 Revenue $50.6M | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -99% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.98% | 277M | C- | ||
| +20.68% | 84.31B | C+ | ||
| -29.31% | 69.9B | B- | ||
| +9.65% | 29.06B | C+ | ||
| -8.63% | 17.38B | B | ||
| +2.14% | 17.01B | A- | ||
| +0.39% | 15.35B | A- | ||
| +6.47% | 12.91B | B- | ||
| +68.23% | 12.47B | C+ | ||
| +6.43% | 12.26B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- VMD Stock
- Ratings Viemed Healthcare, Inc.
